nodes	percent_of_prediction	percent_of_DWPC	metapath
Maprotiline—ABCB1—esophageal cancer	0.542	1	CbGaD
Maprotiline—HTR7—vagus nerve—esophageal cancer	0.0124	0.174	CbGeAlD
Maprotiline—HTR2A—vagus nerve—esophageal cancer	0.00773	0.108	CbGeAlD
Maprotiline—CHRM3—exocrine gland—esophageal cancer	0.00447	0.0626	CbGeAlD
Maprotiline—Alveolitis allergic—Methotrexate—esophageal cancer	0.00418	0.0232	CcSEcCtD
Maprotiline—Sinus tachycardia—Capecitabine—esophageal cancer	0.00364	0.0202	CcSEcCtD
Maprotiline—CHRM5—epithelium—esophageal cancer	0.00348	0.0487	CbGeAlD
Maprotiline—Inappropriate antidiuretic hormone secretion—Cisplatin—esophageal cancer	0.00342	0.019	CcSEcCtD
Maprotiline—Ileus paralytic—Capecitabine—esophageal cancer	0.00339	0.0188	CcSEcCtD
Maprotiline—Depressed mood—Capecitabine—esophageal cancer	0.00328	0.0182	CcSEcCtD
Maprotiline—HTR7—neck—esophageal cancer	0.00272	0.0381	CbGeAlD
Maprotiline—Myoclonus—Capecitabine—esophageal cancer	0.00244	0.0135	CcSEcCtD
Maprotiline—Infection—Carboplatin—esophageal cancer	0.0024	0.0134	CcSEcCtD
Maprotiline—Interstitial pneumonia—Methotrexate—esophageal cancer	0.00226	0.0126	CcSEcCtD
Maprotiline—Bone marrow depression—Capecitabine—esophageal cancer	0.00217	0.0121	CcSEcCtD
Maprotiline—Dysarthria—Cisplatin—esophageal cancer	0.0021	0.0117	CcSEcCtD
Maprotiline—Torsade de pointes—Capecitabine—esophageal cancer	0.00209	0.0116	CcSEcCtD
Maprotiline—CHRM1—trachea—esophageal cancer	0.00192	0.0269	CbGeAlD
Maprotiline—Ventricular fibrillation—Capecitabine—esophageal cancer	0.00191	0.0106	CcSEcCtD
Maprotiline—Body temperature increased—Carboplatin—esophageal cancer	0.00191	0.0106	CcSEcCtD
Maprotiline—CHRM3—smooth muscle tissue—esophageal cancer	0.00187	0.0262	CbGeAlD
Maprotiline—Memory impairment—Capecitabine—esophageal cancer	0.00187	0.0104	CcSEcCtD
Maprotiline—HTR7—epithelium—esophageal cancer	0.00185	0.0259	CbGeAlD
Maprotiline—Tingling sensation—Capecitabine—esophageal cancer	0.00182	0.0101	CcSEcCtD
Maprotiline—HTR7—smooth muscle tissue—esophageal cancer	0.00178	0.025	CbGeAlD
Maprotiline—Petechiae—Capecitabine—esophageal cancer	0.00178	0.00991	CcSEcCtD
Maprotiline—HTR2A—neck—esophageal cancer	0.0017	0.0237	CbGeAlD
Maprotiline—HTR7—trachea—esophageal cancer	0.00164	0.0229	CbGeAlD
Maprotiline—Sertraline—ABCB1—esophageal cancer	0.00163	0.351	CrCbGaD
Maprotiline—ORM1—lung—esophageal cancer	0.00163	0.0228	CbGeAlD
Maprotiline—Bone marrow depression—Methotrexate—esophageal cancer	0.00162	0.00899	CcSEcCtD
Maprotiline—Nasal congestion—Cisplatin—esophageal cancer	0.00158	0.00881	CcSEcCtD
Maprotiline—Dysarthria—Capecitabine—esophageal cancer	0.00155	0.00862	CcSEcCtD
Maprotiline—Interstitial lung disease—Methotrexate—esophageal cancer	0.00154	0.00857	CcSEcCtD
Maprotiline—SLC6A3—lung—esophageal cancer	0.00151	0.0212	CbGeAlD
Maprotiline—Coordination abnormal—Capecitabine—esophageal cancer	0.00149	0.0083	CcSEcCtD
Maprotiline—CHRM3—digestive system—esophageal cancer	0.00148	0.0207	CbGeAlD
Maprotiline—Cerebrovascular accident—Cisplatin—esophageal cancer	0.00147	0.00819	CcSEcCtD
Maprotiline—Blood pressure increased—Capecitabine—esophageal cancer	0.00147	0.00815	CcSEcCtD
Maprotiline—HTR7—digestive system—esophageal cancer	0.00141	0.0197	CbGeAlD
Maprotiline—HRH1—epithelium—esophageal cancer	0.00138	0.0193	CbGeAlD
Maprotiline—CHRM1—lung—esophageal cancer	0.00138	0.0193	CbGeAlD
Maprotiline—HRH1—smooth muscle tissue—esophageal cancer	0.00133	0.0186	CbGeAlD
Maprotiline—Petechiae—Methotrexate—esophageal cancer	0.00133	0.00737	CcSEcCtD
Maprotiline—Orthostatic hypotension—Cisplatin—esophageal cancer	0.00132	0.00733	CcSEcCtD
Maprotiline—Breast disorder—Cisplatin—esophageal cancer	0.0013	0.00725	CcSEcCtD
Maprotiline—Sleep disorder—Capecitabine—esophageal cancer	0.00123	0.00683	CcSEcCtD
Maprotiline—HRH1—trachea—esophageal cancer	0.00122	0.0171	CbGeAlD
Maprotiline—SLC6A2—lung—esophageal cancer	0.00122	0.0171	CbGeAlD
Maprotiline—Sweating increased—Cisplatin—esophageal cancer	0.00121	0.00676	CcSEcCtD
Maprotiline—Bone disorder—Methotrexate—esophageal cancer	0.00121	0.00672	CcSEcCtD
Maprotiline—Vascular purpura—Capecitabine—esophageal cancer	0.00119	0.00661	CcSEcCtD
Maprotiline—Pancytopenia—Cisplatin—esophageal cancer	0.00118	0.00659	CcSEcCtD
Maprotiline—HTR7—lung—esophageal cancer	0.00118	0.0165	CbGeAlD
Maprotiline—HTR2A—epithelium—esophageal cancer	0.00115	0.0162	CbGeAlD
Maprotiline—Dysarthria—Methotrexate—esophageal cancer	0.00115	0.00641	CcSEcCtD
Maprotiline—Libido decreased—Capecitabine—esophageal cancer	0.00115	0.00638	CcSEcCtD
Maprotiline—Hot flush—Capecitabine—esophageal cancer	0.00114	0.00632	CcSEcCtD
Maprotiline—Increased appetite—Capecitabine—esophageal cancer	0.00113	0.0063	CcSEcCtD
Maprotiline—Menopausal symptoms—Capecitabine—esophageal cancer	0.00113	0.00627	CcSEcCtD
Maprotiline—CYP1A2—digestive system—esophageal cancer	0.00112	0.0157	CbGeAlD
Maprotiline—ORM1—lymph node—esophageal cancer	0.00111	0.0156	CbGeAlD
Maprotiline—HTR2A—smooth muscle tissue—esophageal cancer	0.00111	0.0156	CbGeAlD
Maprotiline—DRD2—lung—esophageal cancer	0.00111	0.0156	CbGeAlD
Maprotiline—Purpura—Capecitabine—esophageal cancer	0.0011	0.00614	CcSEcCtD
Maprotiline—Acute coronary syndrome—Cisplatin—esophageal cancer	0.0011	0.0061	CcSEcCtD
Maprotiline—Neuropathy peripheral—Cisplatin—esophageal cancer	0.00109	0.00606	CcSEcCtD
Maprotiline—Myocardial infarction—Cisplatin—esophageal cancer	0.00109	0.00606	CcSEcCtD
Maprotiline—Cerebrovascular accident—Capecitabine—esophageal cancer	0.00109	0.00604	CcSEcCtD
Maprotiline—Stomatitis—Cisplatin—esophageal cancer	0.00108	0.00603	CcSEcCtD
Maprotiline—Osteoarthritis—Capecitabine—esophageal cancer	0.00106	0.00592	CcSEcCtD
Maprotiline—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.00106	0.00587	CcSEcCtD
Maprotiline—Hepatobiliary disease—Cisplatin—esophageal cancer	0.00105	0.00585	CcSEcCtD
Maprotiline—HRH1—digestive system—esophageal cancer	0.00105	0.0147	CbGeAlD
Maprotiline—HTR2A—trachea—esophageal cancer	0.00102	0.0143	CbGeAlD
Maprotiline—Urinary retention—Capecitabine—esophageal cancer	0.00101	0.00563	CcSEcCtD
Maprotiline—Ataxia—Capecitabine—esophageal cancer	0.001	0.00556	CcSEcCtD
Maprotiline—Urinary tract disorder—Cisplatin—esophageal cancer	0.000986	0.00548	CcSEcCtD
Maprotiline—Liver function test abnormal—Capecitabine—esophageal cancer	0.000982	0.00546	CcSEcCtD
Maprotiline—Urethral disorder—Cisplatin—esophageal cancer	0.000978	0.00544	CcSEcCtD
Maprotiline—Gynaecomastia—Methotrexate—esophageal cancer	0.000976	0.00543	CcSEcCtD
Maprotiline—Orthostatic hypotension—Capecitabine—esophageal cancer	0.000971	0.0054	CcSEcCtD
Maprotiline—Breast disorder—Capecitabine—esophageal cancer	0.000961	0.00535	CcSEcCtD
Maprotiline—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	0.000958	0.00533	CcSEcCtD
Maprotiline—Muscular weakness—Capecitabine—esophageal cancer	0.000938	0.00522	CcSEcCtD
Maprotiline—CYP1A2—lung—esophageal cancer	0.000938	0.0131	CbGeAlD
Maprotiline—Protriptyline—ABCB1—esophageal cancer	0.000938	0.202	CrCbGaD
Maprotiline—Eye disorder—Cisplatin—esophageal cancer	0.000933	0.00519	CcSEcCtD
Maprotiline—Tinnitus—Cisplatin—esophageal cancer	0.000931	0.00518	CcSEcCtD
Maprotiline—Cardiac disorder—Cisplatin—esophageal cancer	0.000926	0.00515	CcSEcCtD
Maprotiline—Flushing—Cisplatin—esophageal cancer	0.000926	0.00515	CcSEcCtD
Maprotiline—Dysphagia—Capecitabine—esophageal cancer	0.000919	0.00511	CcSEcCtD
Maprotiline—Bronchospasm—Capecitabine—esophageal cancer	0.000904	0.00503	CcSEcCtD
Maprotiline—Mediastinal disorder—Cisplatin—esophageal cancer	0.0009	0.005	CcSEcCtD
Maprotiline—Sweating increased—Capecitabine—esophageal cancer	0.000895	0.00498	CcSEcCtD
Maprotiline—Arrhythmia—Cisplatin—esophageal cancer	0.000892	0.00496	CcSEcCtD
Maprotiline—Alopecia—Cisplatin—esophageal cancer	0.000882	0.00491	CcSEcCtD
Maprotiline—HTR2A—digestive system—esophageal cancer	0.000878	0.0123	CbGeAlD
Maprotiline—HRH1—lung—esophageal cancer	0.000878	0.0123	CbGeAlD
Maprotiline—Pancytopenia—Capecitabine—esophageal cancer	0.000873	0.00486	CcSEcCtD
Maprotiline—Malnutrition—Cisplatin—esophageal cancer	0.000869	0.00483	CcSEcCtD
Maprotiline—Photosensitivity reaction—Capecitabine—esophageal cancer	0.000839	0.00467	CcSEcCtD
Maprotiline—Weight increased—Capecitabine—esophageal cancer	0.000837	0.00465	CcSEcCtD
Maprotiline—SLC6A2—lymph node—esophageal cancer	0.000835	0.0117	CbGeAlD
Maprotiline—Weight decreased—Capecitabine—esophageal cancer	0.000832	0.00463	CcSEcCtD
Maprotiline—Infestation NOS—Capecitabine—esophageal cancer	0.00082	0.00456	CcSEcCtD
Maprotiline—Infestation—Capecitabine—esophageal cancer	0.00082	0.00456	CcSEcCtD
Maprotiline—Vision blurred—Cisplatin—esophageal cancer	0.000819	0.00455	CcSEcCtD
Maprotiline—Tremor—Cisplatin—esophageal cancer	0.000814	0.00453	CcSEcCtD
Maprotiline—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.000813	0.00452	CcSEcCtD
Maprotiline—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000808	0.00449	CcSEcCtD
Maprotiline—Cerebrovascular accident—Methotrexate—esophageal cancer	0.000808	0.00449	CcSEcCtD
Maprotiline—Myocardial infarction—Capecitabine—esophageal cancer	0.000803	0.00447	CcSEcCtD
Maprotiline—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000803	0.00447	CcSEcCtD
Maprotiline—CYP2D6—digestive system—esophageal cancer	0.0008	0.0112	CbGeAlD
Maprotiline—Stomatitis—Capecitabine—esophageal cancer	0.000799	0.00444	CcSEcCtD
Maprotiline—Jaundice—Capecitabine—esophageal cancer	0.000799	0.00444	CcSEcCtD
Maprotiline—Desipramine—CYP2A6—esophageal cancer	0.000795	0.171	CrCbGaD
Maprotiline—Osteoarthritis—Methotrexate—esophageal cancer	0.000792	0.0044	CcSEcCtD
Maprotiline—Leukopenia—Cisplatin—esophageal cancer	0.000778	0.00433	CcSEcCtD
Maprotiline—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000775	0.00431	CcSEcCtD
Maprotiline—Agranulocytosis—Capecitabine—esophageal cancer	0.000765	0.00425	CcSEcCtD
Maprotiline—ABCB1—epithelium—esophageal cancer	0.000756	0.0106	CbGeAlD
Maprotiline—Convulsion—Cisplatin—esophageal cancer	0.000753	0.00419	CcSEcCtD
Maprotiline—Ataxia—Methotrexate—esophageal cancer	0.000744	0.00414	CcSEcCtD
Maprotiline—Nortriptyline—PTGS1—esophageal cancer	0.000739	0.159	CrCbGaD
Maprotiline—Anxiety—Cisplatin—esophageal cancer	0.000737	0.0041	CcSEcCtD
Maprotiline—Hepatitis—Capecitabine—esophageal cancer	0.000736	0.00409	CcSEcCtD
Maprotiline—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000735	0.00409	CcSEcCtD
Maprotiline—HTR2A—lung—esophageal cancer	0.000733	0.0103	CbGeAlD
Maprotiline—Hypoaesthesia—Capecitabine—esophageal cancer	0.000732	0.00407	CcSEcCtD
Maprotiline—Liver function test abnormal—Methotrexate—esophageal cancer	0.000731	0.00407	CcSEcCtD
Maprotiline—Urinary tract disorder—Capecitabine—esophageal cancer	0.000727	0.00404	CcSEcCtD
Maprotiline—Urethral disorder—Capecitabine—esophageal cancer	0.000721	0.00401	CcSEcCtD
Maprotiline—Breast disorder—Methotrexate—esophageal cancer	0.000715	0.00398	CcSEcCtD
Maprotiline—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.000713	0.00397	CcSEcCtD
Maprotiline—Oedema—Cisplatin—esophageal cancer	0.000709	0.00394	CcSEcCtD
Maprotiline—Infection—Cisplatin—esophageal cancer	0.000704	0.00392	CcSEcCtD
Maprotiline—Erythema multiforme—Capecitabine—esophageal cancer	0.000696	0.00387	CcSEcCtD
Maprotiline—Nervous system disorder—Cisplatin—esophageal cancer	0.000695	0.00387	CcSEcCtD
Maprotiline—Thrombocytopenia—Cisplatin—esophageal cancer	0.000694	0.00386	CcSEcCtD
Maprotiline—Tachycardia—Cisplatin—esophageal cancer	0.000692	0.00385	CcSEcCtD
Maprotiline—Skin disorder—Cisplatin—esophageal cancer	0.000689	0.00383	CcSEcCtD
Maprotiline—Eye disorder—Capecitabine—esophageal cancer	0.000688	0.00382	CcSEcCtD
Maprotiline—Tinnitus—Capecitabine—esophageal cancer	0.000686	0.00382	CcSEcCtD
Maprotiline—Hyperhidrosis—Cisplatin—esophageal cancer	0.000686	0.00381	CcSEcCtD
Maprotiline—Flushing—Capecitabine—esophageal cancer	0.000683	0.0038	CcSEcCtD
Maprotiline—Cardiac disorder—Capecitabine—esophageal cancer	0.000683	0.0038	CcSEcCtD
Maprotiline—Eosinophilia—Methotrexate—esophageal cancer	0.000678	0.00377	CcSEcCtD
Maprotiline—ABCB1—trachea—esophageal cancer	0.000669	0.00936	CbGeAlD
Maprotiline—Angiopathy—Capecitabine—esophageal cancer	0.000668	0.00371	CcSEcCtD
Maprotiline—Mediastinal disorder—Capecitabine—esophageal cancer	0.000663	0.00369	CcSEcCtD
Maprotiline—Hypotension—Cisplatin—esophageal cancer	0.000663	0.00369	CcSEcCtD
Maprotiline—Arrhythmia—Capecitabine—esophageal cancer	0.000657	0.00366	CcSEcCtD
Maprotiline—Alopecia—Capecitabine—esophageal cancer	0.00065	0.00362	CcSEcCtD
Maprotiline—Pancytopenia—Methotrexate—esophageal cancer	0.00065	0.00361	CcSEcCtD
Maprotiline—Malnutrition—Capecitabine—esophageal cancer	0.00064	0.00356	CcSEcCtD
Maprotiline—Paraesthesia—Cisplatin—esophageal cancer	0.000637	0.00354	CcSEcCtD
Maprotiline—Erectile dysfunction—Methotrexate—esophageal cancer	0.00063	0.00351	CcSEcCtD
Maprotiline—Dysgeusia—Capecitabine—esophageal cancer	0.000627	0.00349	CcSEcCtD
Maprotiline—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000625	0.00347	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000612	0.00341	CcSEcCtD
Maprotiline—Drowsiness—Methotrexate—esophageal cancer	0.00061	0.00339	CcSEcCtD
Maprotiline—Infestation—Methotrexate—esophageal cancer	0.00061	0.00339	CcSEcCtD
Maprotiline—Infestation NOS—Methotrexate—esophageal cancer	0.00061	0.00339	CcSEcCtD
Maprotiline—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.000605	0.00336	CcSEcCtD
Maprotiline—Vision blurred—Capecitabine—esophageal cancer	0.000604	0.00336	CcSEcCtD
Maprotiline—HRH1—lymph node—esophageal cancer	0.000601	0.0084	CbGeAlD
Maprotiline—Tremor—Capecitabine—esophageal cancer	0.0006	0.00334	CcSEcCtD
Maprotiline—Stomatitis—Methotrexate—esophageal cancer	0.000595	0.00331	CcSEcCtD
Maprotiline—Feeling abnormal—Cisplatin—esophageal cancer	0.000584	0.00325	CcSEcCtD
Maprotiline—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000577	0.00321	CcSEcCtD
Maprotiline—ABCB1—digestive system—esophageal cancer	0.000575	0.00805	CbGeAlD
Maprotiline—Syncope—Capecitabine—esophageal cancer	0.000574	0.00319	CcSEcCtD
Maprotiline—Leukopenia—Capecitabine—esophageal cancer	0.000573	0.00319	CcSEcCtD
Maprotiline—Agranulocytosis—Methotrexate—esophageal cancer	0.000569	0.00317	CcSEcCtD
Maprotiline—Palpitations—Capecitabine—esophageal cancer	0.000566	0.00315	CcSEcCtD
Maprotiline—Loss of consciousness—Capecitabine—esophageal cancer	0.000563	0.00313	CcSEcCtD
Maprotiline—Body temperature increased—Cisplatin—esophageal cancer	0.000561	0.00312	CcSEcCtD
Maprotiline—Hypertension—Capecitabine—esophageal cancer	0.000553	0.00308	CcSEcCtD
Maprotiline—Hepatitis—Methotrexate—esophageal cancer	0.000548	0.00305	CcSEcCtD
Maprotiline—Anxiety—Capecitabine—esophageal cancer	0.000543	0.00302	CcSEcCtD
Maprotiline—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000542	0.00301	CcSEcCtD
Maprotiline—Urinary tract disorder—Methotrexate—esophageal cancer	0.000541	0.00301	CcSEcCtD
Maprotiline—Urethral disorder—Methotrexate—esophageal cancer	0.000537	0.00299	CcSEcCtD
Maprotiline—Dry mouth—Capecitabine—esophageal cancer	0.000533	0.00297	CcSEcCtD
Maprotiline—Confusional state—Capecitabine—esophageal cancer	0.000527	0.00293	CcSEcCtD
Maprotiline—Oedema—Capecitabine—esophageal cancer	0.000523	0.00291	CcSEcCtD
Maprotiline—Infection—Capecitabine—esophageal cancer	0.000519	0.00289	CcSEcCtD
Maprotiline—Erythema multiforme—Methotrexate—esophageal cancer	0.000518	0.00288	CcSEcCtD
Maprotiline—Shock—Capecitabine—esophageal cancer	0.000514	0.00286	CcSEcCtD
Maprotiline—Nervous system disorder—Capecitabine—esophageal cancer	0.000513	0.00285	CcSEcCtD
Maprotiline—Eye disorder—Methotrexate—esophageal cancer	0.000512	0.00285	CcSEcCtD
Maprotiline—Thrombocytopenia—Capecitabine—esophageal cancer	0.000512	0.00285	CcSEcCtD
Maprotiline—Tinnitus—Methotrexate—esophageal cancer	0.000511	0.00284	CcSEcCtD
Maprotiline—Tachycardia—Capecitabine—esophageal cancer	0.00051	0.00284	CcSEcCtD
Maprotiline—Asthenia—Cisplatin—esophageal cancer	0.000509	0.00283	CcSEcCtD
Maprotiline—Cardiac disorder—Methotrexate—esophageal cancer	0.000508	0.00283	CcSEcCtD
Maprotiline—Skin disorder—Capecitabine—esophageal cancer	0.000508	0.00282	CcSEcCtD
Maprotiline—Hyperhidrosis—Capecitabine—esophageal cancer	0.000505	0.00281	CcSEcCtD
Maprotiline—Angiopathy—Methotrexate—esophageal cancer	0.000497	0.00276	CcSEcCtD
Maprotiline—Mediastinal disorder—Methotrexate—esophageal cancer	0.000494	0.00275	CcSEcCtD
Maprotiline—Hypotension—Capecitabine—esophageal cancer	0.000488	0.00272	CcSEcCtD
Maprotiline—Diarrhoea—Cisplatin—esophageal cancer	0.000485	0.0027	CcSEcCtD
Maprotiline—Alopecia—Methotrexate—esophageal cancer	0.000484	0.00269	CcSEcCtD
Maprotiline—ABCB1—lung—esophageal cancer	0.000481	0.00673	CbGeAlD
Maprotiline—Malnutrition—Methotrexate—esophageal cancer	0.000477	0.00265	CcSEcCtD
Maprotiline—Insomnia—Capecitabine—esophageal cancer	0.000473	0.00263	CcSEcCtD
Maprotiline—Paraesthesia—Capecitabine—esophageal cancer	0.000469	0.00261	CcSEcCtD
Maprotiline—Dysgeusia—Methotrexate—esophageal cancer	0.000467	0.0026	CcSEcCtD
Maprotiline—Dyspepsia—Capecitabine—esophageal cancer	0.00046	0.00256	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000451	0.00251	CcSEcCtD
Maprotiline—Vomiting—Cisplatin—esophageal cancer	0.000451	0.00251	CcSEcCtD
Maprotiline—Fatigue—Capecitabine—esophageal cancer	0.000451	0.00251	CcSEcCtD
Maprotiline—Vision blurred—Methotrexate—esophageal cancer	0.000449	0.0025	CcSEcCtD
Maprotiline—Rash—Cisplatin—esophageal cancer	0.000447	0.00249	CcSEcCtD
Maprotiline—Constipation—Capecitabine—esophageal cancer	0.000447	0.00249	CcSEcCtD
Maprotiline—Dermatitis—Cisplatin—esophageal cancer	0.000447	0.00248	CcSEcCtD
Maprotiline—Feeling abnormal—Capecitabine—esophageal cancer	0.000431	0.0024	CcSEcCtD
Maprotiline—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000427	0.00238	CcSEcCtD
Maprotiline—Leukopenia—Methotrexate—esophageal cancer	0.000427	0.00237	CcSEcCtD
Maprotiline—Nausea—Cisplatin—esophageal cancer	0.000421	0.00234	CcSEcCtD
Maprotiline—Urticaria—Capecitabine—esophageal cancer	0.000415	0.00231	CcSEcCtD
Maprotiline—Abdominal pain—Capecitabine—esophageal cancer	0.000413	0.0023	CcSEcCtD
Maprotiline—Body temperature increased—Capecitabine—esophageal cancer	0.000413	0.0023	CcSEcCtD
Maprotiline—Convulsion—Methotrexate—esophageal cancer	0.000413	0.0023	CcSEcCtD
Maprotiline—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000403	0.00224	CcSEcCtD
Maprotiline—Confusional state—Methotrexate—esophageal cancer	0.000392	0.00218	CcSEcCtD
Maprotiline—Infection—Methotrexate—esophageal cancer	0.000387	0.00215	CcSEcCtD
Maprotiline—Nervous system disorder—Methotrexate—esophageal cancer	0.000382	0.00212	CcSEcCtD
Maprotiline—Thrombocytopenia—Methotrexate—esophageal cancer	0.000381	0.00212	CcSEcCtD
Maprotiline—Skin disorder—Methotrexate—esophageal cancer	0.000378	0.0021	CcSEcCtD
Maprotiline—Hyperhidrosis—Methotrexate—esophageal cancer	0.000376	0.00209	CcSEcCtD
Maprotiline—Asthenia—Capecitabine—esophageal cancer	0.000375	0.00209	CcSEcCtD
Maprotiline—Pruritus—Capecitabine—esophageal cancer	0.00037	0.00206	CcSEcCtD
Maprotiline—Hypotension—Methotrexate—esophageal cancer	0.000364	0.00202	CcSEcCtD
Maprotiline—Diarrhoea—Capecitabine—esophageal cancer	0.000358	0.00199	CcSEcCtD
Maprotiline—Insomnia—Methotrexate—esophageal cancer	0.000352	0.00196	CcSEcCtD
Maprotiline—Paraesthesia—Methotrexate—esophageal cancer	0.000349	0.00194	CcSEcCtD
Maprotiline—Somnolence—Methotrexate—esophageal cancer	0.000346	0.00192	CcSEcCtD
Maprotiline—Dizziness—Capecitabine—esophageal cancer	0.000346	0.00192	CcSEcCtD
Maprotiline—Dyspepsia—Methotrexate—esophageal cancer	0.000343	0.00191	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000336	0.00187	CcSEcCtD
Maprotiline—Fatigue—Methotrexate—esophageal cancer	0.000335	0.00187	CcSEcCtD
Maprotiline—Vomiting—Capecitabine—esophageal cancer	0.000332	0.00185	CcSEcCtD
Maprotiline—Rash—Capecitabine—esophageal cancer	0.00033	0.00183	CcSEcCtD
Maprotiline—Dermatitis—Capecitabine—esophageal cancer	0.000329	0.00183	CcSEcCtD
Maprotiline—ABCB1—lymph node—esophageal cancer	0.000329	0.0046	CbGeAlD
Maprotiline—Headache—Capecitabine—esophageal cancer	0.000327	0.00182	CcSEcCtD
Maprotiline—Feeling abnormal—Methotrexate—esophageal cancer	0.000321	0.00178	CcSEcCtD
Maprotiline—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000318	0.00177	CcSEcCtD
Maprotiline—Nausea—Capecitabine—esophageal cancer	0.00031	0.00173	CcSEcCtD
Maprotiline—Urticaria—Methotrexate—esophageal cancer	0.000309	0.00172	CcSEcCtD
Maprotiline—Body temperature increased—Methotrexate—esophageal cancer	0.000308	0.00171	CcSEcCtD
Maprotiline—Abdominal pain—Methotrexate—esophageal cancer	0.000308	0.00171	CcSEcCtD
Maprotiline—Desipramine—ABCB1—esophageal cancer	0.000296	0.0636	CrCbGaD
Maprotiline—Asthenia—Methotrexate—esophageal cancer	0.000279	0.00155	CcSEcCtD
Maprotiline—Pruritus—Methotrexate—esophageal cancer	0.000275	0.00153	CcSEcCtD
Maprotiline—Diarrhoea—Methotrexate—esophageal cancer	0.000266	0.00148	CcSEcCtD
Maprotiline—Dizziness—Methotrexate—esophageal cancer	0.000257	0.00143	CcSEcCtD
Maprotiline—Imipramine—ABCB1—esophageal cancer	0.000251	0.054	CrCbGaD
Maprotiline—Vomiting—Methotrexate—esophageal cancer	0.000247	0.00138	CcSEcCtD
Maprotiline—Rash—Methotrexate—esophageal cancer	0.000245	0.00136	CcSEcCtD
Maprotiline—Dermatitis—Methotrexate—esophageal cancer	0.000245	0.00136	CcSEcCtD
Maprotiline—Headache—Methotrexate—esophageal cancer	0.000244	0.00136	CcSEcCtD
Maprotiline—Nausea—Methotrexate—esophageal cancer	0.000231	0.00129	CcSEcCtD
Maprotiline—CHRM2—Signaling Pathways—FBXW7—esophageal cancer	3.15e-05	0.000156	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—HIF1A—esophageal cancer	3.14e-05	0.000155	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—CRABP1—esophageal cancer	3.13e-05	0.000155	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—CYP26A1—esophageal cancer	3.12e-05	0.000154	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—ALOX15—esophageal cancer	3.04e-05	0.00015	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—HMOX1—esophageal cancer	3.03e-05	0.00015	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—KDR—esophageal cancer	3e-05	0.000149	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—TGFBR2—esophageal cancer	2.99e-05	0.000148	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—GNG7—esophageal cancer	2.97e-05	0.000147	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—NOTCH2—esophageal cancer	2.97e-05	0.000147	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—HIF1A—esophageal cancer	2.96e-05	0.000147	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—ALDH2—esophageal cancer	2.96e-05	0.000147	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—NOTCH2—esophageal cancer	2.92e-05	0.000145	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—NOTCH2—esophageal cancer	2.92e-05	0.000144	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—ABCB1—esophageal cancer	2.91e-05	0.000144	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—NOTCH2—esophageal cancer	2.91e-05	0.000144	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—NOTCH2—esophageal cancer	2.9e-05	0.000144	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—TPI1—esophageal cancer	2.9e-05	0.000144	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—GSTO1—esophageal cancer	2.9e-05	0.000144	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—NOTCH2—esophageal cancer	2.87e-05	0.000142	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—HIF1A—esophageal cancer	2.84e-05	0.000141	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—KDR—esophageal cancer	2.83e-05	0.00014	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—SMAD4—esophageal cancer	2.83e-05	0.00014	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—NOTCH1—esophageal cancer	2.83e-05	0.00014	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—GSTT1—esophageal cancer	2.81e-05	0.000139	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—ALDH2—esophageal cancer	2.79e-05	0.000138	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—CYP2A6—esophageal cancer	2.78e-05	0.000138	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—ALDOB—esophageal cancer	2.78e-05	0.000138	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—KDR—esophageal cancer	2.71e-05	0.000134	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—GAPDH—esophageal cancer	2.67e-05	0.000132	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—NOTCH1—esophageal cancer	2.67e-05	0.000132	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—GSTT1—esophageal cancer	2.65e-05	0.000131	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—CRABP1—esophageal cancer	2.65e-05	0.000131	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PTGS1—esophageal cancer	2.64e-05	0.000131	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—ENO1—esophageal cancer	2.64e-05	0.000131	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—TGFBR2—esophageal cancer	2.63e-05	0.000131	CbGpPWpGaD
Maprotiline—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	2.63e-05	0.000131	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—CYP2A6—esophageal cancer	2.62e-05	0.00013	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PSME1—esophageal cancer	2.6e-05	0.000129	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PSME2—esophageal cancer	2.6e-05	0.000129	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—TGFBR2—esophageal cancer	2.59e-05	0.000128	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—TGFBR2—esophageal cancer	2.59e-05	0.000128	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—TGFBR2—esophageal cancer	2.58e-05	0.000128	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—TGFBR2—esophageal cancer	2.57e-05	0.000127	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—CREBBP—esophageal cancer	2.56e-05	0.000127	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—NOTCH1—esophageal cancer	2.56e-05	0.000127	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—TGFBR2—esophageal cancer	2.55e-05	0.000126	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—GNG7—esophageal cancer	2.52e-05	0.000125	CbGpPWpGaD
Maprotiline—HTR7—Signaling by GPCR—EGFR—esophageal cancer	2.52e-05	0.000125	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—SMAD4—esophageal cancer	2.49e-05	0.000124	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—ENO1—esophageal cancer	2.48e-05	0.000123	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PTGS1—esophageal cancer	2.48e-05	0.000123	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—SMAD4—esophageal cancer	2.45e-05	0.000122	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—SMAD4—esophageal cancer	2.45e-05	0.000121	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PSME1—esophageal cancer	2.45e-05	0.000121	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PSME2—esophageal cancer	2.45e-05	0.000121	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—SMAD4—esophageal cancer	2.44e-05	0.000121	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—SMAD4—esophageal cancer	2.43e-05	0.000121	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—CREBBP—esophageal cancer	2.42e-05	0.00012	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—SMAD4—esophageal cancer	2.41e-05	0.000119	CbGpPWpGaD
Maprotiline—HTR7—GPCR downstream signaling—PIK3CA—esophageal cancer	2.41e-05	0.000119	CbGpPWpGaD
Maprotiline—CHRM4—Signaling by GPCR—EGFR—esophageal cancer	2.38e-05	0.000118	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—ALDH2—esophageal cancer	2.36e-05	0.000117	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—CREBBP—esophageal cancer	2.32e-05	0.000115	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—HIF1A—esophageal cancer	2.31e-05	0.000115	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—NOS3—esophageal cancer	2.29e-05	0.000114	CbGpPWpGaD
Maprotiline—CHRM5—Signaling by GPCR—EGFR—esophageal cancer	2.28e-05	0.000113	CbGpPWpGaD
Maprotiline—CHRM4—GPCR downstream signaling—PIK3CA—esophageal cancer	2.27e-05	0.000113	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—GSTT1—esophageal cancer	2.25e-05	0.000111	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—CYP1B1—esophageal cancer	2.24e-05	0.000111	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—CYP2A6—esophageal cancer	2.22e-05	0.00011	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.21e-05	0.00011	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—KDR—esophageal cancer	2.21e-05	0.00011	CbGpPWpGaD
Maprotiline—HTR7—Signaling by GPCR—PIK3CA—esophageal cancer	2.18e-05	0.000108	CbGpPWpGaD
Maprotiline—CHRM5—GPCR downstream signaling—PIK3CA—esophageal cancer	2.18e-05	0.000108	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—NOS3—esophageal cancer	2.17e-05	0.000107	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—ERBB2—esophageal cancer	2.15e-05	0.000106	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—CYP1B1—esophageal cancer	2.11e-05	0.000105	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—CYP19A1—esophageal cancer	2.11e-05	0.000104	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—ENO1—esophageal cancer	2.1e-05	0.000104	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PTGS1—esophageal cancer	2.1e-05	0.000104	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—NOTCH1—esophageal cancer	2.08e-05	0.000103	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—NOS3—esophageal cancer	2.07e-05	0.000103	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PSME1—esophageal cancer	2.07e-05	0.000103	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PSME2—esophageal cancer	2.07e-05	0.000103	CbGpPWpGaD
Maprotiline—CHRM4—Signaling by GPCR—PIK3CA—esophageal cancer	2.06e-05	0.000102	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—HIF1A—esophageal cancer	2.04e-05	0.000101	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—ERBB2—esophageal cancer	2.03e-05	0.0001	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—HIF1A—esophageal cancer	2.01e-05	9.95e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—HIF1A—esophageal cancer	2e-05	9.93e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—HIF1A—esophageal cancer	2e-05	9.89e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—HIF1A—esophageal cancer	1.99e-05	9.86e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—CYP19A1—esophageal cancer	1.99e-05	9.84e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling by GPCR—PIK3CA—esophageal cancer	1.98e-05	9.79e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—HIF1A—esophageal cancer	1.97e-05	9.77e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—KDR—esophageal cancer	1.95e-05	9.67e-05	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—CREBBP—esophageal cancer	1.94e-05	9.63e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—ERBB2—esophageal cancer	1.94e-05	9.61e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—HMOX1—esophageal cancer	1.92e-05	9.53e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—KDR—esophageal cancer	1.92e-05	9.51e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—KDR—esophageal cancer	1.92e-05	9.49e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—KDR—esophageal cancer	1.91e-05	9.46e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—KDR—esophageal cancer	1.9e-05	9.43e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—CCND1—esophageal cancer	1.9e-05	9.39e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—CREBBP—esophageal cancer	1.89e-05	9.36e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—KDR—esophageal cancer	1.89e-05	9.34e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling by GPCR—EGFR—esophageal cancer	1.86e-05	9.19e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—NOTCH1—esophageal cancer	1.84e-05	9.11e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—CDKN1A—esophageal cancer	1.83e-05	9.08e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—HMOX1—esophageal cancer	1.81e-05	8.98e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.81e-05	8.97e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—NOTCH1—esophageal cancer	1.81e-05	8.96e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—NOTCH1—esophageal cancer	1.8e-05	8.94e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—NOTCH1—esophageal cancer	1.8e-05	8.91e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—NOTCH1—esophageal cancer	1.79e-05	8.88e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—CCND1—esophageal cancer	1.79e-05	8.87e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—CYP1B1—esophageal cancer	1.79e-05	8.87e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—NOTCH1—esophageal cancer	1.78e-05	8.8e-05	CbGpPWpGaD
Maprotiline—HTR2C—GPCR downstream signaling—PIK3CA—esophageal cancer	1.77e-05	8.79e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—EP300—esophageal cancer	1.74e-05	8.64e-05	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—NOS3—esophageal cancer	1.74e-05	8.63e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—ABCB1—esophageal cancer	1.74e-05	8.62e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—CDKN1A—esophageal cancer	1.73e-05	8.58e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—CCND1—esophageal cancer	1.71e-05	8.49e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—NOS3—esophageal cancer	1.69e-05	8.38e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—CYP19A1—esophageal cancer	1.68e-05	8.34e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—CREBBP—esophageal cancer	1.67e-05	8.26e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—CDKN1A—esophageal cancer	1.66e-05	8.21e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—EP300—esophageal cancer	1.65e-05	8.16e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—CREBBP—esophageal cancer	1.64e-05	8.12e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling by GPCR—EGFR—esophageal cancer	1.64e-05	8.11e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—CREBBP—esophageal cancer	1.64e-05	8.11e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—CREBBP—esophageal cancer	1.63e-05	8.08e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—CREBBP—esophageal cancer	1.63e-05	8.06e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling by GPCR—EGFR—esophageal cancer	1.61e-05	7.98e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling by GPCR—PIK3CA—esophageal cancer	1.61e-05	7.98e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—CREBBP—esophageal cancer	1.61e-05	7.98e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—EGFR—esophageal cancer	1.61e-05	7.97e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—EGFR—esophageal cancer	1.6e-05	7.94e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—EGFR—esophageal cancer	1.6e-05	7.92e-05	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—PTGS2—esophageal cancer	1.59e-05	7.89e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—EGFR—esophageal cancer	1.58e-05	7.84e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—ERBB2—esophageal cancer	1.58e-05	7.84e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—EP300—esophageal cancer	1.58e-05	7.82e-05	CbGpPWpGaD
Maprotiline—DRD2—GPCR downstream signaling—PIK3CA—esophageal cancer	1.57e-05	7.75e-05	CbGpPWpGaD
Maprotiline—HTR2A—GPCR downstream signaling—PIK3CA—esophageal cancer	1.54e-05	7.63e-05	CbGpPWpGaD
Maprotiline—HRH1—GPCR downstream signaling—PIK3CA—esophageal cancer	1.54e-05	7.61e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—HMOX1—esophageal cancer	1.54e-05	7.61e-05	CbGpPWpGaD
Maprotiline—CHRM1—GPCR downstream signaling—PIK3CA—esophageal cancer	1.53e-05	7.59e-05	CbGpPWpGaD
Maprotiline—CHRM3—GPCR downstream signaling—PIK3CA—esophageal cancer	1.53e-05	7.57e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—MYC—esophageal cancer	1.52e-05	7.53e-05	CbGpPWpGaD
Maprotiline—CHRM2—GPCR downstream signaling—PIK3CA—esophageal cancer	1.51e-05	7.49e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.51e-05	7.46e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—NOS3—esophageal cancer	1.49e-05	7.39e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—EGFR—esophageal cancer	1.49e-05	7.37e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—ABCB1—esophageal cancer	1.47e-05	7.3e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—NOS3—esophageal cancer	1.47e-05	7.27e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—NOS3—esophageal cancer	1.47e-05	7.26e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—NOS3—esophageal cancer	1.46e-05	7.24e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—NOS3—esophageal cancer	1.46e-05	7.21e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—NOS3—esophageal cancer	1.44e-05	7.14e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—MYC—esophageal cancer	1.44e-05	7.11e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling by GPCR—PIK3CA—esophageal cancer	1.42e-05	7.04e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—EGFR—esophageal cancer	1.4e-05	6.96e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling by GPCR—PIK3CA—esophageal cancer	1.4e-05	6.93e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—CCND1—esophageal cancer	1.4e-05	6.92e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—ERBB2—esophageal cancer	1.4e-05	6.91e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—PIK3CA—esophageal cancer	1.4e-05	6.91e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—PIK3CA—esophageal cancer	1.39e-05	6.89e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—PIK3CA—esophageal cancer	1.39e-05	6.87e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—MYC—esophageal cancer	1.37e-05	6.81e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—ERBB2—esophageal cancer	1.37e-05	6.8e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—PIK3CA—esophageal cancer	1.37e-05	6.8e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—ERBB2—esophageal cancer	1.37e-05	6.79e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—ERBB2—esophageal cancer	1.37e-05	6.77e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—ERBB2—esophageal cancer	1.36e-05	6.75e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—CDKN1A—esophageal cancer	1.35e-05	6.7e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—ERBB2—esophageal cancer	1.35e-05	6.68e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—EGFR—esophageal cancer	1.34e-05	6.66e-05	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—EP300—esophageal cancer	1.32e-05	6.56e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—PIK3CA—esophageal cancer	1.29e-05	6.39e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—EP300—esophageal cancer	1.29e-05	6.37e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—TP53—esophageal cancer	1.25e-05	6.19e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—CREBBP—esophageal cancer	1.23e-05	6.11e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—CCND1—esophageal cancer	1.23e-05	6.11e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—PIK3CA—esophageal cancer	1.22e-05	6.04e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—CCND1—esophageal cancer	1.21e-05	6.01e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—CCND1—esophageal cancer	1.21e-05	6e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—CCND1—esophageal cancer	1.21e-05	5.98e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—CCND1—esophageal cancer	1.2e-05	5.96e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—CDKN1A—esophageal cancer	1.19e-05	5.91e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—CCND1—esophageal cancer	1.19e-05	5.9e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—TP53—esophageal cancer	1.18e-05	5.84e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—CDKN1A—esophageal cancer	1.17e-05	5.82e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—CDKN1A—esophageal cancer	1.17e-05	5.8e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—CDKN1A—esophageal cancer	1.17e-05	5.78e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—PIK3CA—esophageal cancer	1.17e-05	5.78e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—CDKN1A—esophageal cancer	1.16e-05	5.77e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—CREBBP—esophageal cancer	1.16e-05	5.76e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—CDKN1A—esophageal cancer	1.15e-05	5.71e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—EP300—esophageal cancer	1.14e-05	5.62e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—TP53—esophageal cancer	1.13e-05	5.59e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—MYC—esophageal cancer	1.12e-05	5.55e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—EP300—esophageal cancer	1.12e-05	5.53e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—EP300—esophageal cancer	1.11e-05	5.52e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.11e-05	5.52e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—EP300—esophageal cancer	1.11e-05	5.5e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—EP300—esophageal cancer	1.11e-05	5.49e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—NOS3—esophageal cancer	1.1e-05	5.47e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—EP300—esophageal cancer	1.1e-05	5.43e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—EGFR—esophageal cancer	1.1e-05	5.43e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—NOS3—esophageal cancer	1.04e-05	5.16e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PTGS2—esophageal cancer	1.01e-05	5.01e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—MYC—esophageal cancer	9.89e-06	4.9e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—CREBBP—esophageal cancer	9.85e-06	4.88e-05	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—PIK3CA—esophageal cancer	9.8e-06	4.85e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—MYC—esophageal cancer	9.73e-06	4.82e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—MYC—esophageal cancer	9.71e-06	4.81e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—MYC—esophageal cancer	9.68e-06	4.8e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—EGFR—esophageal cancer	9.68e-06	4.79e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—MYC—esophageal cancer	9.65e-06	4.78e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—MYC—esophageal cancer	9.56e-06	4.73e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PTGS2—esophageal cancer	9.52e-06	4.72e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—EGFR—esophageal cancer	9.52e-06	4.72e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—PIK3CA—esophageal cancer	9.51e-06	4.71e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—EGFR—esophageal cancer	9.5e-06	4.71e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—EGFR—esophageal cancer	9.47e-06	4.69e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—EGFR—esophageal cancer	9.44e-06	4.68e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—EGFR—esophageal cancer	9.35e-06	4.63e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—TP53—esophageal cancer	9.2e-06	4.56e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—NOS3—esophageal cancer	8.82e-06	4.37e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—EP300—esophageal cancer	8.4e-06	4.16e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—PIK3CA—esophageal cancer	8.4e-06	4.16e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—PIK3CA—esophageal cancer	8.26e-06	4.09e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—PIK3CA—esophageal cancer	8.24e-06	4.08e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—PIK3CA—esophageal cancer	8.22e-06	4.07e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—PIK3CA—esophageal cancer	8.19e-06	4.06e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—TP53—esophageal cancer	8.12e-06	4.02e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—PIK3CA—esophageal cancer	8.11e-06	4.02e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PTGS2—esophageal cancer	8.07e-06	4e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—TP53—esophageal cancer	7.99e-06	3.96e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—TP53—esophageal cancer	7.98e-06	3.95e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—TP53—esophageal cancer	7.95e-06	3.94e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—TP53—esophageal cancer	7.92e-06	3.93e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—EP300—esophageal cancer	7.92e-06	3.92e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—TP53—esophageal cancer	7.85e-06	3.89e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—EP300—esophageal cancer	6.71e-06	3.32e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PIK3CA—esophageal cancer	6.22e-06	3.08e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PIK3CA—esophageal cancer	5.86e-06	2.9e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PIK3CA—esophageal cancer	4.96e-06	2.46e-05	CbGpPWpGaD
